Marburg, October 13, 2020, AGCT tested its novel EGFR prototype kit together with a German cancer research institute and HistogeneX, a global CRO laboratory supporting diagnostic and clinical studies in oncology with headquarters in Antwerp/Belgium. The results with non-clinical human DNA samples demonstrate cyberPCR’s high sensitivity with extreme wildtype DNA background and its superiority in a head-to-head comparison with today’s standard assays for real-time PCR and digital PCR platforms.Dirk Loeffert, AGCT’s COO, who brings along almost 20 years of product development know-how from his former position at Qiagen, is verySEE DETAIL...

Marburg, January 3, 2019, AGCT closes financing round to accelerate revolutionary assay technology development for oncology market    AGCT announces the closing of a substantial financing round with existing investors and two investment companies. The financing followed a technology milestone achievement demonstrating the performance of AGCT’s proprietary cyberPCR technology. cyberPCR is a novel PCR-based method that AGCT believes has the power to significantly improve the early detection of circulating tumor DNA from cancer liquid biopsies over existing assay technologies. The unique advantage of cyberPCR is the exclusive amplification of tumor-derived DNASEE DETAILS <span class="more-link-image...